Open AccessP934: DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN
Author(s) -
Rodriguez C.,
Kaufman J. L.,
Laubach J.,
Sborov D. W.,
Reeves B.,
Chari A.,
Silbermann R.,
Costa L. J.,
Anderson L. D.,
Nathwani N.,
Shah N.,
Bumma N.,
Jakubowiak A.,
Orlowski R. Z.,
Pei H.,
Cortoos A.,
Patel S.,
Lin T. S.,
Richardson P. G.,
Voorhees P. M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846604.67185.0c
Subject(s) - lenalidomide , medicine , daratumumab , bortezomib , multiple myeloma , minimal residual disease , gastroenterology , dexamethasone , surgery , oncology , bone marrow